"rationale","name","instanceType","label","id","uuid:ID","description"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1","StudyDesign","","StudyDesign_1","39ebcfc2-9f31-4ee6-b329-5955003c06c2","The main design for the study"
